Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2025

Description

Systemic aspergillosis, the most lethal form of aspergillosis, occurs when the infection extends beyond the lungs to affect other organs. On the other hand, systemic candidiasis encompasses a range of yeast infections caused by various Candida species. Both conditions are serious illnesses capable of damaging organs such as the blood, heart, brain, eyes, bones, and others.

The primary types of treatments for systemic aspergillosis and systemic candidiasis include systemic oral azoles, voriconazole, liposomal amphotericin B, topical antifungal agents, and others. Systemic oral azoles constitute a class of antifungal medications taken orally to combat systemic fungal infections throughout the body. These drugs target specific enzymes crucial for fungal survival, thereby inhibiting the growth and replication of fungal cells. They find application in treating conditions such as allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and others. The usage is prevalent in clinics, hospitals, and other healthcare settings.

The systemic aspergillosis and systemic candidiasis research report is one of a series of new reports from The Business Research Company that provides systemic aspergillosis and systemic candidiasis market statistics, including the systemic aspergillosis and systemic candidiasis industry's global market size, regional shares, competitors with systemic aspergillosis and systemic candidiasis market share, detailed systemic aspergillosis and systemic candidiasis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic aspergillosis and systemic candidiasis industry. This systemic aspergillosis and systemic candidiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The systemic aspergillosis and systemic candidiasis market size has grown steadily in recent years. It will grow from $7.24 billion in 2024 to $7.59 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing incidence of fungal infections, immunocompromised patient population, improved diagnostic technologies, rise in invasive medical procedures, global spread of infections

The systemic aspergillosis and systemic candidiasis market size is expected to see strong growth in the next few years. It will grow to $9.28 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to global antifungal resistance surveillance, aging population, telemedicine for remote consultations, patient-centric drug development, digital health solutions for patient management. Major trends in the forecast period include new fungal biomarkers for early detection, the emergence of novel antifungal agents, advancements in immunotherapy, and innovative drug delivery systems.

The rising incidence of fungal diseases is projected to drive the growth of the systemic aspergillosis and systemic candidiasis market in the future. Fungal diseases are infections caused by fungi that can impact various parts of the body, leading to a range of symptoms and complications. These infections can manifest as cutaneous skin infections, respiratory issues, and systemic conditions. Treatment typically involves antifungal medications, including oral azoles, voriconazole, and liposomal amphotericin B. For example, in July 2024, *The Lancet*, a respected medical journal based in London, reported estimates indicating there are 6.5 million cases of invasive fungal infections each year, resulting in 3.8 million deaths, with approximately 2.5 million of these fatalities directly attributed to the infections. Consequently, the rising incidence of fungal diseases is fueling the growth of the systemic aspergillosis and systemic candidiasis market.

The escalation in healthcare expenditures is anticipated to stimulate the growth of the systemic aspergillosis and systemic candidiasis market in the future. Healthcare expenditures refer to the total amount of money allocated for medical services, treatments, and health-related expenses over a specific period. Increased healthcare spending can facilitate the management of systemic aspergillosis and systemic candidiasis by providing timely access to antifungal medications, advanced diagnostic tools, and specialized care, thus improving patient outcomes and lowering mortality rates. For instance, in May 2023, a report from the Office for National Statistics, a UK government department, revealed that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth of 0.9% in 2022. The UK's healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the increase in healthcare spending is contributing to the growth of the systemic aspergillosis and systemic candidiasis market.

Leading companies in the systemic aspergillosis and systemic candidiasis markets are focusing on developing advanced products like echinocandins to improve treatment efficacy and tackle the increasing challenges posed by antifungal resistance. Echinocandins represent a class of antifungal medications that inhibit the synthesis of B-glucan, a vital component of the fungal cell wall. For example, in March 2023, Cidara Therapeutics and Melinta Therapeutics, both US-based biotechnology firms, received approval from the Food and Drug Administration (FDA), the federal agency responsible for public health protection in the US, for REZZAYO (rezafungin for injection). REZZAYO is an innovative once-weekly echinocandin aimed at treating candidemia in adults who have limited or no alternative treatment options. Its once-weekly dosing regimen is designed for ease of administration, streamlining treatment and improving continuity of care for patients with invasive candidiasis, especially those in hospital environments where effective infection management is essential.

Major companies in the systemic aspergillosis and systemic candidiasis market are also focusing on advanced solutions, such as next-generation anti-fungal drug agents, to address the growing demand for more effective and targeted treatments. Next-generation anti-fungal drug agents involve advanced medications designed to combat fungal infections more effectively, often incorporating innovative mechanisms or formulations to enhance efficacy and reduce resistance. For example, in October 2023, BDR Pharmaceutical, a US-based pharmaceutical company, launched Zisavel capsules for treating invasive aspergillosis and mucormycosis. This product, belonging to the isavuconazoles class of medications, plays a crucial role in treating invasive aspergillosis and offers a first-line treatment for the specified fungal infections.

In August 2023, Sandoz, a global pharmaceutical company based in Germany, acquired Astellas Pharma Inc. for an undisclosed sum. This acquisition is intended to significantly enhance Sandoz's hospital offerings and broaden its anti-infectives portfolio, allowing the company to deliver essential antimicrobial medicines and promote responsible use through targeted therapies for patients in need. Astellas Pharma Inc., a global pharmaceutical company based in Japan, specializes in treatments for systemic aspergillosis and systemic candidiasis.

Major companies operating in the systemic aspergillosis and systemic candidiasis market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the systemic aspergillosis and systemic candidiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The systemic aspergillosis and systemic candidiasis market consists of sales of voriconazole and amphotericin B. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on systemic aspergillosis and systemic candidiasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for systemic aspergillosis and systemic candidiasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The systemic aspergillosis and systemic candidiasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Systemic Oral Azoles; Voriconazole; Liposomal Amphotericin B; Topical Antifungal Agents; Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA); Chronic Pulmonary Aspergillosis (CPA); Gastrointestinal Candidiasis; Genitourinary Tract Candidiasis; Other Applications
3) By End User: Clinic; Hospital; Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole; Itraconazole; Posaconazole; Voriconazole
2) By Voriconazole: Voriconazole Tablets; Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis; Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles; Topical Polyenes; Topical Allylamines
5) By Other Types: Echinocandins; Antifungal Combination Therapies; Other Emerging Antifungal Agents
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25343

1. Executive Summary

2. Systemic Aspergillosis And Systemic Candidiasis Market Characteristics

3. Systemic Aspergillosis And Systemic Candidiasis Market Trends And Strategies

4. Systemic Aspergillosis And Systemic Candidiasis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Systemic Aspergillosis And Systemic Candidiasis Growth Analysis And Strategic Analysis Framework

5.1. Global Systemic Aspergillosis And Systemic Candidiasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Systemic Aspergillosis And Systemic Candidiasis Market Growth Rate Analysis
5.4. Global Systemic Aspergillosis And Systemic Candidiasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Systemic Aspergillosis And Systemic Candidiasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Systemic Aspergillosis And Systemic Candidiasis Total Addressable Market (TAM)

6. Systemic Aspergillosis And Systemic Candidiasis Market Segmentation

6.1. Global Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Synthetic Colour
Enzymes
Hydrocolloids
Antioxidants
Flavor And Fragrances
6.2. Global Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic Pulmonary Aspergillosis (CPA)
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
Other Applications
6.3. Global Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinic
Hospital
Other End Users
6.4. Global Systemic Aspergillosis And Systemic Candidiasis Market, Sub-Segmentation Of Systemic Oral Azoles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluconazole
Itraconazole
Posaconazole
Voriconazole
6.5. Global Systemic Aspergillosis And Systemic Candidiasis Market, Sub-Segmentation Of Voriconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Voriconazole Tablets
Voriconazole Injection
6.6. Global Systemic Aspergillosis And Systemic Candidiasis Market, Sub-Segmentation Of Liposomal Amphotericin B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Liposomal Amphotericin B For Systemic Aspergillosis
Liposomal Amphotericin B For Systemic Candidiasis
6.7. Global Systemic Aspergillosis And Systemic Candidiasis Market, Sub-Segmentation Of Topical Antifungal Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topical Azoles
Topical Polyenes
Topical Allylamines
6.8. Global Systemic Aspergillosis And Systemic Candidiasis Market, Sub-Segmentation Of Other Types, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Echinocandins
Antifungal Combination Therapies
Other Emerging Antifungal Agents

7. Systemic Aspergillosis And Systemic Candidiasis Market Regional And Country Analysis

7.1. Global Systemic Aspergillosis And Systemic Candidiasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Systemic Aspergillosis And Systemic Candidiasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Systemic Aspergillosis And Systemic Candidiasis Market

8.1. Asia-Pacific Systemic Aspergillosis And Systemic Candidiasis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Systemic Aspergillosis And Systemic Candidiasis Market

9.1. China Systemic Aspergillosis And Systemic Candidiasis Market Overview
9.2. China Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Systemic Aspergillosis And Systemic Candidiasis Market

10.1. India Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Systemic Aspergillosis And Systemic Candidiasis Market

11.1. Japan Systemic Aspergillosis And Systemic Candidiasis Market Overview
11.2. Japan Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Systemic Aspergillosis And Systemic Candidiasis Market

12.1. Australia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Systemic Aspergillosis And Systemic Candidiasis Market

13.1. Indonesia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Systemic Aspergillosis And Systemic Candidiasis Market

14.1. South Korea Systemic Aspergillosis And Systemic Candidiasis Market Overview
14.2. South Korea Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Systemic Aspergillosis And Systemic Candidiasis Market

15.1. Western Europe Systemic Aspergillosis And Systemic Candidiasis Market Overview
15.2. Western Europe Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Systemic Aspergillosis And Systemic Candidiasis Market

16.1. UK Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Systemic Aspergillosis And Systemic Candidiasis Market

17.1. Germany Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Systemic Aspergillosis And Systemic Candidiasis Market

18.1. France Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Systemic Aspergillosis And Systemic Candidiasis Market

19.1. Italy Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Systemic Aspergillosis And Systemic Candidiasis Market

20.1. Spain Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Systemic Aspergillosis And Systemic Candidiasis Market

21.1. Eastern Europe Systemic Aspergillosis And Systemic Candidiasis Market Overview
21.2. Eastern Europe Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Systemic Aspergillosis And Systemic Candidiasis Market

22.1. Russia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Systemic Aspergillosis And Systemic Candidiasis Market

23.1. North America Systemic Aspergillosis And Systemic Candidiasis Market Overview
23.2. North America Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Systemic Aspergillosis And Systemic Candidiasis Market

24.1. USA Systemic Aspergillosis And Systemic Candidiasis Market Overview
24.2. USA Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Systemic Aspergillosis And Systemic Candidiasis Market

25.1. Canada Systemic Aspergillosis And Systemic Candidiasis Market Overview
25.2. Canada Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Systemic Aspergillosis And Systemic Candidiasis Market

26.1. South America Systemic Aspergillosis And Systemic Candidiasis Market Overview
26.2. South America Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Systemic Aspergillosis And Systemic Candidiasis Market

27.1. Brazil Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Systemic Aspergillosis And Systemic Candidiasis Market

28.1. Middle East Systemic Aspergillosis And Systemic Candidiasis Market Overview
28.2. Middle East Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Systemic Aspergillosis And Systemic Candidiasis Market

29.1. Africa Systemic Aspergillosis And Systemic Candidiasis Market Overview
29.2. Africa Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Systemic Aspergillosis And Systemic Candidiasis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Systemic Aspergillosis And Systemic Candidiasis Market Competitive Landscape And Company Profiles

30.1. Systemic Aspergillosis And Systemic Candidiasis Market Competitive Landscape
30.2. Systemic Aspergillosis And Systemic Candidiasis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Systemic Aspergillosis And Systemic Candidiasis Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. Abbott Laboratories
31.3. Sanofi S.A.
31.4. GlaxoSmithKline PLC
31.5. Gilead Sciences Inc.
31.6. Regeneron Pharmaceuticals Inc.
31.7. Astellas Pharma Inc.
31.8. Matinas BioPharma Holdings Inc.
31.9. Shionogi & Co. Ltd
31.10. Cipla Limited
31.11. Taj Pharmaceuticals Limited
31.12. Basilea Pharmaceutica Ltd.
31.13. Cidara Therapeutics Inc.
31.14. T2 Biosystems Inc.
31.15. Sandoz International GmbH

32. Global Systemic Aspergillosis And Systemic Candidiasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Systemic Aspergillosis And Systemic Candidiasis Market

34. Recent Developments In The Systemic Aspergillosis And Systemic Candidiasis Market

35. Systemic Aspergillosis And Systemic Candidiasis Market High Potential Countries, Segments and Strategies

35.1 Systemic Aspergillosis And Systemic Candidiasis Market In 2029 - Countries Offering Most New Opportunities
35.2 Systemic Aspergillosis And Systemic Candidiasis Market In 2029 - Segments Offering Most New Opportunities
35.3 Systemic Aspergillosis And Systemic Candidiasis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer